SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)

RCT 47 ICU patients showing no significant differences with vitamin C treatment.

Although the 19% lower mortality is not statistically significant, it is consistent with the significant 20% lower mortality [10‑28%] from meta analysis of the 46 mortality results to date.

This is the 21st COVID-19 RCT for vitamin C, which collectively show efficacy with p=0.0012.

This is the 70th of 75 COVID-19 controlled studies for vitamin C, which collectively show efficacy with p=0.00000002 (1 in 50 million).

Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments. This may explain in part the very high mortality seen in this study. Results may differ in countries with improved SOC.

This study is excluded in the after exclusion results of meta analysis: very late stage, ICU patients.